Paper Details

  1. Home
  2. Paper Details

Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial.

Author: ColePatricia E, KappelerChristian, KussIris, MazibukoNdaba, O'DalyOwen, PatrickFiona, WilliamsSteven C R, ZurthChristian

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase I, randomized, placebo-controlled, three-period crossover study compared cerebral blood flow (CBF) in grey matter and specific regions related to cognition after darolutamide, enzalutamide, or placebo administration in healthy males. Darolutamide did not significantly alter CBF, consistent with its low blood-brain barrier penetration and low risk of CNS-related adverse events. A significant reduction in CBF was observed with enzalutamide. These results may be relevant to cognitive function with early and extended use of second-generation AR inhibitors, and warrant further investigation in patients with prostate cancer.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Off-target central nervous system (CNS) effects are associated with androgen receptor (AR)-targeting treatments for prostate cancer. Darolutamide is a structurally distinct AR inhibitor with low blood-brain barrier penetration. OBJECTIVE: We compared cerebral blood flow (CBF) in grey ma...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191908/

データ提供：米国国立医学図書館（NLM）

Darolutamide vs. Enzalutamide: A Brain Scan Comparison

The desert of prostate cancer treatment can be vast and unforgiving, with potential side effects lurking like mirages. This research delves into the impact of androgen receptor (AR)-targeting treatments on brain blood flow. The study uses a crossover trial design to compare the effects of two AR inhibitors, darolutamide and enzalutamide, on cerebral blood flow (CBF) in healthy volunteers. The researchers found that enzalutamide caused a significant reduction in CBF in certain brain regions compared to darolutamide and a placebo, while darolutamide had minimal impact on CBF. The findings suggest that darolutamide, with its lower blood-brain barrier penetration, may have a lower risk of central nervous system (CNS)-related side effects.

Navigating the Desert with Caution

This study emphasizes the importance of understanding the potential impact of prostate cancer treatments on the brain. While both darolutamide and enzalutamide are effective treatments, the study suggests that darolutamide may be a safer option in terms of minimizing CNS-related side effects.

Protecting the Oasis

The desert of prostate cancer treatment can be daunting, but research like this helps us identify safe and effective solutions. It reminds us of the importance of carefully navigating the landscape of treatment options, considering potential side effects and choosing treatments that minimize risks.

Dr. Camel's Conclusion

This research provides valuable insights into the potential impact of androgen receptor inhibitors on brain blood flow. The findings highlight the importance of considering the CNS effects of various treatments, particularly for patients with prostate cancer. This research underscores the need for personalized approaches to treatment, taking into account individual needs and risks. As always, consulting with a medical professional is crucial for navigating the desert of prostate cancer treatment and finding the best path forward.
Date :
  1. Date Completed 2023-05-19
  2. Date Revised 2023-05-31
Further Info :

Pubmed ID

37103658

DOI: Digital Object Identifier

PMC10191908

Related Literature

Article Analysis
・Effects of darolutamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.